

बिज़नेस स्टैंडर्ड



www.bshindi.com



► पृष्ठ 4
बिजली की राह चला
सार्वजनिक परिवहन

नरेंद्र मोदी ► पृष्ठ 15

इंजीनियरिंग का उत्कृष्ट
नमूना सरदार सरोवर बांध

एक नज़र

अमेरिकी फेडरल रिजर्व पर रहेगी बाजार की नजर

इस सप्ताह शेयर बाजार की दिशा मुख्य रूप से कोरियाई प्रायद्वीप में भू-राजनीतिक गतिविधियों और अमेरिकी फेडरल रिजर्व की बैठक के नतीजे से तय होगी। शेरों संकेतों के अलावा अिससे खासकर तेल के दाम में तेजी कुल मिलाकर बाजार धारणा को प्रभावित करेगा।

जीएसटीएन कंपोजिशन स्कीम अब 30 सितंबर तक

जीएसटी नेटवर्क (जीएसटीएन) ने रविवार को कहा कि उसने 75 लाख रुपये तक कारोबार करने वाले छोटे व्यापारियों के लिए कंपोजिशन स्कीम की सुविधा अपनाया का विकल्प फिर से उपलब्ध कराई है। यह योजना 30 सितंबर तक खुली रहेगी।

न्यूतन राशि शुल्क की समीक्षा कर रहा एसबीआई

भारतीय स्टेट बैंक ने कहा कि वह उपभोक्ताओं की प्रतिक्रिया मिलने के बाद मासिक औसत राशि बचकार नहीं रखने पर लागू होने वाले शुल्क की समीक्षा कर रहा है। बैंक के प्रबंध निदेशक (ग्रुप्यु बैंकिंग समूह) रजनीश कुमार ने इसकी जानकारी दी।

आज का सवाल

क्या एसबीआई न्यूनतम बैलेंस शुल्क हटाने का करे निर्णय?

www.bshindi.com पर राय भेजें।
आप अपना अवयव एड्रेसपर और कर सकते हैं।
यदि आपका अवयव हो है तो BSP और यदि न है तो BSP N लिखकर 57007 पर भेजें।

विपरीत सवाल का नतीजा


क्या निर्यात में तेजी बचकरार हों 66.67%
रहने से घटेगा व्यापार घाटा? नहीं 33.33%

पूँजीकरण में अव्वल वित्तीय फर्में

कुल बाजार पूँजीकरण में बैंक और एनबीएफसी की हिस्सेदारी अब सबसे ऊंचे स्तर पर

कृपा कांत
मुंबई, 17 सितंबर

भारत में ऋण या कर्ज देने वाला क्षेत्र तेजी से विकास कर रहा है और इस क्षेत्र की सफल कंपनियों पर हाल के दिनों में इन्वेंचर निवेशकों का दुखार भी उमड़ रहा है। सभी सूचीबद्ध कंपनियों के कुल बाजार पूँजीकरण में बैंकों और गैर-बैंकिंग वित्तीय कंपनियों (एनबीएफसी) की हिस्सेदारी सर्वश्रेष्ठ उच्च स्तर पर पहुंच गई है क्योंकि विनिर्माण और गैर-वित्तीय कंपनियों जैसे कि सूचना प्रौद्योगिकी क्षेत्र को कमजोर मांग का सामना करना पड़ रहा है।



बैंकों और बीमा कंपनियों सहित एनबीएफसी का समेकित बाजार पूँजीकरण मार्च 2014 के 17.2 फीसदी और मार्च 2012 के 17.3 फीसदी से बढ़कर 22.3 फीसदी हो गया है, जो पिछले दो दशक में सर्वाधिक है। दूसरी ओर विनिर्माण कंपनियों का बाजार पूँजीकरण घटकर इस साल के निचले स्तर 54 फीसदी पर आ गया है जबकि वित्त वर्ष 2014 के अंत में यह 55 फीसदी और पांच साल पहले करीब 57 फीसदी थी।

बाजार पूँजीकरण में सबसे ज्यादा गिरावट गैर-वित्तीय सेवा क्षेत्र की कंपनियों टाटा कंसल्टेंसी, इन्फोसिस और विप्रो आदि में आई है। गैर-वित्तीय सेवा

क्षेत्र की कंपनियों का बाजार पूँजीकरण घटकर सबसे निचले स्तर 23.7 फीसदी पर आ गया है, जो तीन साल पहले 28 फीसदी पर था। बैंकों और एनबीएफसी का समेकित बाजार पूँजीकरण पिछले तीन साल में 145 फीसदी बढ़कर 30.4 लाख करोड़ रुपये पहुंच गया है और मार्च 2014 से इसमें सालाना 29 फीसदी की दर से इजाफा हो रहा है। इसी अवधि में विनिर्माण कंपनियों का समेकित बाजार पूँजीकरण 85 फीसदी बढ़कर 73.6 लाख करोड़ रुपये रहा और इस दौरान सालाना आधार पर इसमें 19.2 फीसदी की वृद्धि देखी गई।

हालांकि बाजार पूँजीकरण में इस तेजी का ज्यादा फायदा सार्वजनिक क्षेत्र के बैंकों को नहीं मिला पाया है क्योंकि वे मुख्य रूप से ऋण देने के कारोबार से जुड़े हैं और कॉर्पोरेट क्षेत्र को और से लाना निवेश नहीं होने से कर्ज को मांग में नरमी का रुख बना हुआ है। गैर-वित्तीय सेवा क्षेत्र का बाजार पूँजीकरण इस दौरान 61 फीसदी बढ़कर 32.4 लाख करोड़ रुपये रहा और मार्च 2014 से सालाना आधार पर इसमें महज 14.6 फीसदी की दर से इजाफा हुआ है। यह विश्लेषण सक्रिय रूप से कारोबार करने वाली कंपनियों के वित्त वर्ष 1994-95 से साल के अंत में बाजार पूँजीकरण और राजस्व के आधार पर किया गया है। इसका मतलब यह हुआ कि नमूने का आकार हर साल बढ़ता

आय हिस्सेदारी से तय होगी ताज की नीलामी

निवेदिता मुखर्जी
नई दिल्ली, 17 सितंबर

करीब 40 साल बाद ताजमहल होटल (ताज मानसिंह) की नीलामी की तैयारी की जा रही है और इसके लिए नियम एवं शर्तों को अंतिम रूप दिया जा रहा है। सूत्रों के अनुसार पूँजीकरण के प्रतिष्ठित पर आधारीत है। भले ही कुल आंकड़ों में ऐसा नजर नहीं आता हो लेकिन रिटेल फाइनेंस में आई तेजी विनिर्माण और सेवा क्षेत्र जैसे संबंधित क्षेत्रों में भी दिखनी शुरू हो गई है। उदाहरण के लिए इस समय सबसे ज्यादा तेजी यात्रा कारों और दोपहिया वाहन सहित टिकाऊ उपभोक्ता वस्तुओं और संगठित खुदरा क्षेत्र में दिख रही है। इन क्षेत्रों में लोन के जरिये खरीद की जाती है।



अगले महीने शुरू हो सकती है होटल ताज मानसिंह की नीलामी, बोली से तय होगी राजस्व साझेदारी

विशेषज्ञों का मानना है कि भारतीय अर्थव्यवस्था में फाइनेंस का जोर बढ़ रहा है और औद्योगिक विकास तथा सेवा निर्यात में लगातार उछाल आ चुका है। इन्वेंचर निवेशक रिस्चर्व एंड एडवाइजरी के संस्थापक एवं प्रबंध निदेशक जी चैककालिंगम ने कहा, 'निजी क्षेत्र के बैंक और खुदरा गैर बैंकिंग फाइनेंस के कंपनियों लगातार वृद्धि हासिल कर रही हैं जबकि बाकी अर्थव्यवस्था में उछाल की स्थिति है। इसलिए वित्तीय कंपनियों निवेशकों को चहती बनी हुई हैं।' (शेष पृष्ठ 9)

राजस्व हिस्सेदारी के औसत के बराबर रकम का एकमुष्ट भुगतान डेढ़ साल में करना होगा। गैर-टाटा कंपनी के नीलामी जीते से राजस्व में हिस्सेदारी की शुरुआत 18 महीने के बाद शुरू होगी, जो कंपनी के लिए लाभकारी होगा। टाटा के मामले में पहले दिन से ही राजस्व-साझेदारी का प्रबंधन होगा। सूत्रों ने कहा कि टाटा समूह के लिए ताज मानसिंह प्रतिष्ठित संपत्ति है और यह इस ब्रांड को अपने साथ बनाए रखने का कोशिश कर सकता है। एसबीआई कैपेस नीलामी प्रक्रिया का संचालन करेगी और टाटा के पास नीलामी प्रक्रिया में पहले इनकार का अधिकार नहीं होगा। (शेष पृष्ठ 11)

SBI Life

INSURANCE

With Us, You're Sure

www.sbilife.co.in

There is a lot in this life.

Celebrate life

Parentage
State Bank of India & BNP Paribas Cardif S.A.

Partnership
Serving the community across India

Products
Comprehensive portfolio of 37 individual and group products*

Presence
Multichannel distribution network of 95,177 agents* and 803 branch offices* across India

*As of July 31, 2017

SBI LIFE INSURANCE COMPANY LIMITED is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to make an initial public offer of its Equity Shares and has registered the Red Herring Prospectus dated September 11, 2017 with the Registrar of Companies, Maharashtra at Mumbai on September 12, 2017 (the "RHP"). The RHP is available on the websites of SEBI, and the Stock Exchanges at www.sebi.gov.in, www.bseindia.com, www.nseindia.com, respectively, and at the websites of the Lead Managers at www.jifm.com, www.axiscapital.co.in, www.bnparibas.co.in, www.online.citicbank.co.in, www.dli.com/india, www.icicisecurities.com, www.investmenbank.kotak.com and www.sbicaps.com, respectively. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risks, see the section titled "Risk Factors" beginning on page 20 of the RHP. The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws in the United States, and unless so registered may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold only to "qualified institutional buyers" (as such term is defined in Rule 144A under the U.S. Securities Act) in reliance on the exemption from the registration requirements of the U.S. Securities Act or another available exemption from registration under the U.S. Securities Act and outside of the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act and the applicable laws of the jurisdiction where those offers and sales are made. There will be no public offering of the Equity Shares in the United States. SBI Life Insurance Company Limited. Trade logo displayed above belongs to State Bank of India and is used by SBI Life under license.

BWARE OF SPURIOUS PHONE CALLS AND FICTITIOUS/FRAUDULENT OFFERS: IRDAI clarifies to public that • IRDAI or its officials do not involve in activities like sale of any kind of insurance or financial products nor invest premiums. • IRDAI does not announce any bonus. • Public receiving such phone calls are requested to lodge a police complaint along with details of phone call, number.


For more details on risk factors, terms & conditions, please read the sales brochure carefully before concluding a sale. Past performance is not indicative of future performance. Trade logo displayed above belongs to State Bank of India and is used by SBI Life under license. SBI Life Insurance Company Limited, Registered & Corporate Office: Natraj, M. V. Road & Western Express Highway Junction, Andheri (East), Mumbai - 400 069. IRDAI Regd. No. 111. CIN: U99999MH2000PLC121913. Toll free: 1800 22 9090 (Between 9:00 am to 9:00 pm) E-mail: info@sbilife.co.in | SMS: 'CELEBRATE' to 56161

COR.IPO.ver.02-09/17 ADVT ENG



LASA SUPERGENERICS LIMITED

B / 207, City Point, J B Nagar Andheri (E), Mumbai 400059, Tel: +91- 7798888147 / +91-22-43701092, e-mail: cs@lasalabs.com, www.lasalabs.com



WORLD'S FACTORY FOR VETERINARY MEDICINE

Leader in Veterinary API Market, a high entry barrier Business
Niche player in the API Vet industry, 35% market share in the Animal healthcare market
Established player with a niche mix of high quality product portfolio.

Strong Technical know how of Catalytic Chemistry
Rich Management experience of over 2 decades in catalytic chemistry
Use of catalysts significantly reduces cost of raw material time, curtails toxic concentration in effluents and enhances yields.

Fully Backward Integrated and Fungible and Manufacturing Facilities
Differentiating edge. Each process starts from the basic petrochemical derivatives, enhancing yields, creating scale and Operating efficiencies Four fully vertically units in Chiplun and Mahad (Maharashtra).

Strong and Nice product portfolio
13 products with high opportunity and demand in Domestic Global Market
No product dependency, top 7 Segments contribute to 80% of topline.

Esteemed and Diversified Clientele. Domestic and Global
Over 400 domestic and Global customers across product portfolio
Global footprint across 27 countries.

Stringent Regulatory Norms already in place
Certified facility leading to greater market access 4 FDA approved pharma zones
10 DMF approved products; 7 process patent in Pipeline.

Strong R & D capabilities, well equipped inhouse R & D center
Consortium of technocrats with cumulative experience spanning over 200 years, work in tandem, to develop catalysts and patent processes, to create a high yielding, better quality products.

Lets Grow Together. Listing Soon

STATUTORY ADVERTISEMENT ISSUED IN COMPLIANCE OF SEBI CIRCULAR NO. SEBI/CFD/SCRR/01/2009/03/09 DATED SEPTEMBER 03, 2009 AND CFD/DIL/3/CIR/2017/21 DATED MARCH 10, 2017 PURSUANT TO THE GRANT OF RELAXATION BY SECURITIES AND EXCHANGE BOARD OF INDIA (SEBI) VIDE THEIR LETTER NO. CFD/DIL-1/BNS/AKD/22048/2017 DATED SEPTEMBER 13, 2017 FROM THE APPLICABILITY OF THE RULE 192(b) OF THE SECURITIES CONTRACTS (REGULATIONS) RULES, 1957.

A. NAME AND ADDRESS OF ITS REGISTERED OFFICE:

Lasa Supergenics Limited was incorporated as a public limited company on March 11, 2016 (Company Registration Number: 274202 and having Corporate Identification Number: U24233MH2016PLC274202) under the Companies Act, 2013 with the Registrar of Companies, Mumbai, Maharashtra ("RoC")
Registered Office: C-105, MIDC Mahad, Raigad, Maharashtra – 402301

B. DETAILS OF CHANGE OF NAME AND/OR OBJECT CLAUSE: No change in name and/or object clause.

C. CAPITAL STRUCTURE - PRE AND POST SCHEME OF ARRANGEMENT:

Share Capital of the Company Pre Scheme	Aggregate Value at Face Value (Rs.)
Authorized Share Capital	
Equity Shares 3,50,00,000 of Rs. 10/-	35,00,00,000
Total	35,00,00,000
Issued, Subscribed and Paid-up Share Capital	
Equity Shares 50,00,000 of Rs. 10/-	5,00,00,000
Total	5,00,00,000
Share Capital of the Company Post Scheme	Aggregate Value at Face Value (Rs.)
Authorized Share Capital	
Equity Shares 3,50,00,000 of Rs. 10/-	35,00,00,000
Total	35,00,00,000
Issued, Subscribed and Paid-up Share Capital	
Equity Shares 2,28,64,449 of Rs. 10/-	22,86,44,490
Total	22,86,44,490

D. SHAREHOLDING PATTERN OF THE PROMOTER AND PROMOTER GROUP:

Sr. No.	Promoter	Number of shares held	% Held
1	Omkar Herlekar	52,51,500	22.97
2	Pravin Herlekar	21,00,821	9.18
3	Rishikesh Herlekar	5,17,006	2.26
Promoter Group Companies			
4	Omkar Speciality Chemicals Limited	22,86,445	10.00
5	Svaks Biotech India Private Limited	3,80,000	1.66

E. NAME OF TEN LARGEST SHAREHOLDERS:

Sr. No.	Name of the shareholder	No. Of shares	% of equity capital	Interest in the company
1	Omkar Pravin Herlekar	52,51,500	22.97	Promoter, Chairman & Managing Director
2	Omkar Speciality Chemicals Limited	22,86,445	10.00	Promoter Group Company
3	Pravin Shivdas Herlekar	21,00,821	9.18	Promoter
4	Rishikesh Pravin Herlekar	5,17,006	2.26	Promoter
5	Svaks Biotech India Private Limited	3,80,000	1.66	Promoter Group Company
6	Sunil Jain	1,05,501	0.46	-
7	Deenar Krishnarao Toraskar	1,00,803	0.44	-
8	Bodhviriksha Advisors LLP	1,00,000	0.43	-
9	Anugrah Stock & Broking Pvt Ltd	97,860	0.43	-
10	Mohammed Arshad	97,184	0.42	-

F. DETAILS OF PROMOTERS:

1) **Omkar P. Herlekar** is the Chairman and Managing Director of Lasa Supergenics Limited. Upon assuming the leadership of Lasa, he charted a multi-pronged approach for its corporate growth. Envisioning a global presence for the group, he played a pivotal role in establishing marketing set-up and four subsidiaries across India and globally. Lasa places immense focus on research. He has played a pivotal role in embryonic the group's 'Catalyst Chemistry' division that focuses on development of veterinary APIs and breakthrough innovations. His contributions are widely acclaimed in the industry circles. Under his leadership, Lasa achieved number of milestones and offered several innovations with the help of 'backward integration'.
Mr. Herlekar's visionary and astute entrepreneurial leadership resulted in Lasa emerging as one of the leading animal healthcare conglomerates in India, driven by research, and strategic thinking on a global scale. His clear vision, steady guidance and boundless passion for organic chemistry serve as catalysts for the steady and continued expansion of the group.

2) **Pravin Herlekar** is a Bachelor of Technology in Chemical Engineering from Indian Institute of Technology (IIT), Bombay and is a Post Graduate in Management Studies from Mumbai University. He has an overall experience of over 4 decades in the field of Product Development, Marketing and Administration.

3) **Rishikesh Herlekar** is a B.E. (Chemicals) graduate and pursuing M. Tech in Pharmaceutical Sciences. He is also involved in Accounting, Audit & Finance area. Coordinating with Production, Quality Production, Quality Assurance and related Regulatory Matters.

G. BUSINESS

Lasa Supergenics Limited ('Lasa') is a vertically integrated group spanning the entire veterinary, animal and human healthcare value chain—from discovery-to-delivery, with established credentials in research, manufacturing and global marketing. Lasa group is a veterinary API manufacturing entity, which was acquired in April 2012. The manufacturing base of Lasa group is located at Mahad, in the Konkan region of Maharashtra. It specialises in 'catalyst chemistry' and manufactures anthelmintic/ veterinary API products with the largest production capabilities and product categories in India. To efficiently control the supply chain, the group backward integrated its key molecules - from discovery research up to full-scale bulk production. Lasa group's marketing footprint is entrenched across developing markets in multiple countries. Similarly, the group expects to augment its export footprint significantly in width and depth in the future. The group has alliances with leading Indian and global animal health care conglomerates, and uses Good Manufacturing Practice (GMP) and world-class technologies in its operations. Lasa group is managed by a consortium of technocrats, including its Chairman and Managing Director Mr. Omkar P. Herlekar who is impelled by passion and propelled by niche innovation. Our leadership team, which is guided by these values, is well positioned to lead the group into the future. Looking ahead, Lasa group is determined to achieve its goal of becoming a leading force in the niche animal health care solutions. The objective on which the group was founded have always inspired sustainable growth through innovation in the last four years, and shall continue to do so in times to come.



Name	Designation
1) Mr. Omkar Herlekar	Chairman & Managing Director
2) Mr. Shivamand Hegde	Whole-Time Director
3) Mr. Sumant Kharasamle	Whole-Time Director
4) Mr. Harshad Tolani	Independent Director
5) Mr. Ajay Sukhwani	Independent Director
6) Ms. Ekta Gurnisinghani	Independent Director
7) Mr. Hitesh Wadhvani	Company Secretary and Compliance Officer
8) Mr. Mitesh Bhosle	Chief Financial Officer

H. REASON FOR THE AMALGAMATION:

Omkar Speciality Chemicals Limited basically had two businesses with divergent business profile, growth potential, risk-rewards, regulatory and capital requirements and are largely independent of each other. With a primary intention of achieving operational efficiencies, it has been decided by the management of OSCL to demerge the Veterinary API undertaking into Lasa Supergenerics Limited. In consideration of the above mentioned business rationale and related benefits, this Scheme between Lasa Laboratory Private Limited, Urdhwa Chemical Company Private Limited, Rishichem, Research Limited, Dsh Chemicals Private Limited, Lasa Supergenerics Limited and Omkar Speciality Chemicals Limited is being proposed in accordance with the terms set out.

I. FINANCIAL STATEMENTS OF THE COMPANY:

Particulars	Balance Sheet (Rs in Lakhs)	
	As at March 31 2017	As at March 31 2016
Shareholder's Funds		
Share Capital	5.00	5.00
Share capital suspense account	2,057.80	-
Reserves and Surplus	5,491.17	-
	7,553.97	5.00
Non-Current Liabilities		
Long-term borrowings	8,465.76	35.04
Deferred tax liabilities (Net)	12.87	-
Long term provisions	125.81	-
	8,604.44	35.04
Current Liabilities		
Short-term borrowings	2,318.51	-
Trade payables	2,538.40	-
Other current liabilities	1,330.76	0.05
Short-term provisions	369.19	-
	6,556.85	0.05
TOTAL	22,715.26	40.09
Non-current Assets		
Fixed assets		
Tangible assets	11,285.57	-
Intangible assets	421.23	-
Capital work-in-progress	2,950.73	-
Non-current investments	0.10	-
Long term loans and advances	49.81	-
Other Non Current Assets	28.09	35.09
	14,735.53	35.09
Current Assets		
Inventories	3,345.85	-
Trade receivables	3,504.17	-
Cash and cash equivalent	116.23	5.00
Short-term loans and advances	883.43	-
Other current assets	130.05	-
	7,979.73	5.00
TOTAL	22,715.26	40.09

J. LATEST AUDITED FINANCIAL STATEMENTS

Particulars	Note No.	Balance Sheet (Rs in Lakhs)	
		As at March 31 2017	As at March 31 2016
Shareholder's Funds			
Share Capital	3(a)	5.00	5.00
Share capital suspense account	3(b)	2,057.80	-
Reserves and Surplus	4	5,491.17	-
		7,553.97	5.00
Non-Current Liabilities			
Long-term borrowings	5	8,465.76	35.04
Deferred tax liabilities (Net)	6	12.87	-
Long term provisions	7	125.81	-
		8,604.44	35.04
Current Liabilities			
Short-term borrowings	5	2,318.51	-
Trade payables	8	2,538.40	-
Other current liabilities	9	1,330.76	0.05
Short-term provisions	10	369.19	-
		6,556.85	0.05
TOTAL		22,715.26	40.09
Non-current Assets			
Fixed assets			
Tangible assets	11(a)	11,285.57	-
Intangible assets	11(b)	421.23	-
Capital work-in-progress	11(c)	2,950.73	-
Non-current investments	12	0.10	-
Long term loans and advances	13	49.81	-
Other Non Current Assets	14	28.09	35.09
		14,735.53	35.09
Current Assets			
Inventories	15	3,345.85	-
Trade receivables	16	3,504.17	-
Cash and cash equivalents	17	116.23	5.00
Short-term loans and advances	18	883.43	-
Other current assets	19	130.05	-
		7,979.73	5.00
TOTAL		22,715.26	40.09

Notes on Financial Statements 1 to 34

1. GENERAL INFORMATION

Lasa Supergenerics Limited ('Lasa' or the 'Company'), having registered address at H No 10/1, Kedar Co-op Hsg Soc, Shirgaon, Kulgaon (E) Badlapur Thane, carries on business of antihelmintics/veterinary API & manufacturer of Bulk Drugs. The Company was incorporated under the Companies Act, 2013 on March 11, 2016

1.B. SCHEME OF ARRANGEMENT:

a) The Board of Directors of Lasa Supergenerics Limited ('LASA') the company, has approved the Composite Scheme of Arrangement ('the Scheme') Veterinary API Undertaking of Omkar Speciality Chemicals Limited to Lasa Supergenerics Limited for merger of with the Company with effect from appointed date April 1, 2015. The Hon'ble High Court of Bombay has approved the Scheme vide its order dated April 27, 2017.

b) In terms of the Scheme, all assets, liabilities and reserves of Veterinary API undertaking of Omkar Speciality Chemicals Limited (OSCL) have been vested with the Company with effect from April 1, 2015 and have been recorded at their respective book values in accordance with the Scheme.

c) All the inter-company balances between the Company and its API unit taken from OSCL as at April 1, 2014 stand cancelled.

d) The Company will issue 2,05,78,000 equity shares of Rs. 10- each, fully paid-up, of the Company to the holders of Equity shares of OSCL whose names will be registered in the register of members on the record date, without payment being received in cash, in the ratio of 1 (one) fully paid-up equity shares of Rs. 10- each of the Company for every 1 (one) fully paid-up equity shares of Rs. 1 held in LASA. Pending issue of such shares as at March 31, 2017, the face value of shares to be issued has been accounted under Share Capital Suspense Account (Refer notes 3(a) & 3(b))

e) Accordingly, in terms of the Scheme, after giving effect to the aforesaid, the difference has been adjusted against the Capital Reserve Account as under 1B(i):

2. Significant Accounting Policies

i. BASIS OF PREPARATION OF FINANCIAL STATEMENTS

The financial statements are prepared under the historical cost convention in accordance with the generally accepted accounting principles in India, the provisions of the companies Act, 2013 and the applicable accounting standards. The company follows mercantile system of accounting and recognizes income and expenditure on accrual basis.

ii. USE OF ESTIMATES

The preparation of financial statements requires estimates and assumptions that affect the reported amount of Assets and Liabilities on the date of the financial statements and the reported amount of Revenues and Expenses during the reporting period. Difference between the actual results and the estimates are recognized in the period in which the same are known/materialized.

iii. FIXED ASSETS

1. Fixed Assets are stated at cost of acquisition or construction (net of CENVAT/VAT credit availed) less accumulated depreciation/amortization and impairment loss, if any. Cost included all direct and indirect costs relating to the acquisition and installation of fixed assets, interest on borrowed funds, if any, used to finance/construction of fixed assets ready for commercial use. Leasehold land is amortized over the period of lease.

2. Cost comprises of purchase price and any attributable cost of bringing the asset to its working condition for its intended use.

3. Capital work-in-progress comprises cost of fixed assets that are not yet ready for their intended use at the year end.

iv. INVENTORIES

1. Raw Material
The company is valuing Raw material, packing material and stores stock by taking costs of purchase consist of the purchase price including duties and taxes (other than those subsequently recoverable by the enterprise from the taxing authorities), freight inwards and other expenditure directly attributable to the acquisition. Trade discounts, rebates, duty drawbacks, finance cost and other similar items are deducted in determining value of the stock of Raw materials. In determining the cost the First In First Out (FIFO) method is used.

2. Finished Goods and Work in process:
Finished Goods and Work in process are valued at cost or net realizable value, whichever is lower. The cost is determined by reducing from the sales value of inventory the appropriate percentage of gross margin depending on the stage of completion.

v. REVENUE RECOGNITION

1. Revenue from sale of goods is recognized when the significant risks and rewards in respect of ownership of products are transferred by the company.

2. Revenue from product sale is stated net of returns, sales tax/VAT and applicable trade discounts and allowances.

3. Interest income is recognized on time accrual basis.

vi. INVESTMENTS

1. Investments that are readily realisable and intended to be held for not more than one year from the date of investment are classified as current investments. All other investments are classified as long-term investments.

2. Current investments are carried at the lower of cost and realisable value, determined on an individual investment basis in respect of each category of investment.

3. Long-term investments are carried at cost less any other-than-temporary diminution in value, determined separately in respect of each category of investment.

vii. DEPRECIATION/AMORTIZATION

Depreciation on all fixed assets is provided as per the provisions of Companies Act, 2013 on Straight Line Method. Depreciation is calculated on pro-rata basis from month of installation till the month of the assets are sold/dropped off. The useful life of leasehold improvements are estimated taking into consideration lease period including the renewal option.

viii. EMPLOYEE BENEFITS:

1. Short Term Employee Benefits:
All short-term employee benefits such as salaries, wages, bonus, special awards, medical benefits which fall due within twelve months of the period in which the employee renders the related services which entitles him to avail such benefits and non-accumulating compensated absences are recognized on an undiscounted basis charged to the profit and loss account.

(i) Defined contribution plans

The Company has defined contribution plan for post employment benefits in the form of provident fund. The Company's contributions to defined contribution plans are charged to the Statement of Profit and Loss as incurred.

(ii) Defined benefit plans

The Company has defined benefit plans for post employment benefits in the form of gratuity and compensated absences. Liability for defined benefit plans is provided on the basis of valuations, as at the Balance Sheet date, carried out by an independent actuary and contributed to employees Gratuity Fund. The actuarial valuation method used for measuring the liability is the projected unit credit method.

(iii) Compensated absences

The Company provides for the encashment of leave with pay subject to certain rules. The employees are entitled to accumulate leave subject to certain limits, for future encashment /avaiement. The liability is provided based on the number of days of unutilized leave at each Balance Sheet date on the basis of an independent actuarial valuation.

ix. TAXES ON INCOME

Income Taxes are accounted for in accordance with Accounting Standard 22 (AS 22) "Accounting for Taxes on Income". Tax expense comprises of Current Tax and Deferred Tax:

1. Current Tax is determined as the amount of tax payable in respect of taxable income for the year.
2. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to Timing Differences, between the taxable income and accounting income, that originate in one period and are capable of reversal in one or more periods. Deferred tax assets are recognised only to the extent there is reasonable certainty that the assets can be realized in the future, however when there is unabsorbed depreciation or carry forward loss under taxation laws, deferred tax assets are recognised only if there is a virtual certainty of realisation of such assets. Deferred tax assets are reviewed as at each balance sheet date and written down or written-up to reflect the amount that is reasonably /virtually certain (as the case may be) to be realised."

Statement of Profit and Loss (Rs in Lakhs)

Particulars	Note No.	Statement of Profit and Loss (Rs in Lakhs)	
		Year Ended March 31 2017	Year Ended March 31 2016
INCOME			
Revenue from operations	20	19,966.25	-
Other Income	21	27.18	-
Total Revenue		19,993.43	-
EXPENDITURE			
Cost of materials consumed	22	14,167.04	-
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	23	(1,078.36)	-
Employee benefit expense	24	978.91	-
Financial costs	25	932.06	-
Depreciation and amortization expense	11	863.51	-
Other expenses	26	1,370.60	-
Total Expenditure		17,233.75	-
Profit before Exceptional Items and Tax		2,759.67	-
Exceptional items	27	3,061.30	-
Profit before Tax		(301.62)	-
Tax expense:			
Current tax	-	-	-
Deferred tax	6	(241.80)	-
Adjustment of tax of previous years (Net)		2.71	-
Profit for the period		(62.53)	-
Earnings per equity share (in Rs)	33		
Basic		(125.07)	-
Diluted		(125.07)	-

Statement of Profit and Loss (Rs in Lakhs)

Particulars	Statement of Profit and Loss (Rs in Lakhs)	
	Year Ended March 31 2017	Year Ended March 31 2016
INCOME		
Revenue from operations	19,966.25	-
Other Income	27.18	-
Total Revenue	19,993.43	-
EXPENDITURE		
Cost of materials consumed	14,167.04	-
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(1,078.36)	-
Employee benefit expense	978.91	-
Financial costs	932.06	-
Depreciation and amortization expense	863.51	-
Other expenses	1,370.60	-
Total Expenditure	17,233.75	-
Profit before Exceptional Items and Tax	2,759.67	-
Exceptional items	3,061.30	-
Profit before Tax	(301.62)	-
Tax expense:		
Current tax	-	-
Deferred tax	(241.80)	-
Adjustment of tax of previous years (Net)	2.71	-
Profit for the period	(62.53)	-
Earnings per equity share (in Rs)		
Basic	(125.07)	-
Diluted	(125.07)	-

Cash Flow Statement (Rs. In Lakhs)

Particulars	Cash Flow Statement (Rs. In Lakhs)	
	March 31 2017	March 31 2016
A. Cash Flow from Operating Activities		
Net Profit before Tax	(302)	-
Adjustment for:		
Arising pursuant to the scheme of arrangement	890	-
Depreciation for the year	863	-
CWIP written back	2,619	-
Interest Expenses	861	-
Provision for Gratuity	28	-
(Gain)/ Loss on account of Fixed Assets	2	-
Operating Profit Before Working Capital Changes	4,871	-
Adjustments for (increase) / decrease in operating assets:		
Trade Receivables	(1,364)	-
Inventories	(1,364)	-
Margin money with banks	-	-
Short Term Loans and Advances	392	-
Long Term Loans & Advances	12	-
Other Current Assets	(99)	-
Other Non Current Assets	7	(35)
Adjustments for increase / (decrease) in operating liabilities:		
Trade payables	(652)	-
Other current liabilities	606	0
Short-term provisions	100	-
Other long term liabilities	-	-
Cash Generated from Operations	2510	(35)
Income Tax Paid	(8)	-
Net cash flow from Operating activities (A)	2502	(35)
B. Cash Flow from Investing Activities		
Purchase of Fixed Assets/ Capital Expenditure	(2,834)	-
Proceeds from sale of Motor car	4	-
Net Cash used in Investing Activities	(28,29)	-
C. Cash Flow from Financing Activities		
Proceeds from other long-term borrowings	745	35
Proceeds from other short-term borrowings	555	-
Money received from Fresh Issue of Equity Shares	-	5
Interest Paid	(861)	-
Net Cash used in Financing Activities	439	40
Net Increase (-Decrease) in Cash & Cash Equivalents (A+B-C)	111	5
Cash & Cash Equivalent at the beginning of the Year	5	-
Cash & Cash Equivalent at the end of the Year	116	5

1B(i): Particulars

Particulars	Amount
Book value of assets, liabilities and reserves of API Undertaking Assets	
Tangible assets	10,428.72
Intangible assets	402.05
Capital work-in-progress	2,288.08
Non-current investments	0.10
Long term loans and advances	61.08
Inventories	3,409.94
Trade receivables	1,815.54
Cash and cash equivalents	321.15
Short-term loans and advances	1,516.00
Other current assets	55.85
Total (i)	20,298.51
Liabilities	
Long-term borrowings	6,768.05
Deferred tax liabilities (Net)	(145.66)
Long term provisions	27.77
Short-term borrowing	1,993.16
Trade payables	3,107.53
Other current liabilities	401.23
Short-term provisions	534.93
Total (ii)	12,687.01
Equity and Reserves	
Equity	2,057.80
Capital Reserve	5,553.70

x. PROVISIONS, CONTINGENT LIABILITIES AND CONTINGENT ASSETS

Provisions involving substantial degree of estimation in measurement are recognized when there is a present obligation as a result of past events and it is probable that there will be an outflow of resources. Contingent liabilities are not recognized but are disclosed in the Notes to Accounts. Contingent Assets are neither recognized nor disclosed in the financial statements.

xi. BORROWING COST

Borrowing cost attributable to acquisitions and construction of capital goods are capitalized as a part of cost of such assets up to the date when such assets are ready for its intended use and all other borrowing costs are charged to profit & loss account.

xii. IMPAIRMENT OF ASSETS

The Company assesses at each Balance Sheet date whether there is any indication that an asset may be impaired. If any such indication exists, the Company estimates the recoverable amount of the asset. If such recoverable amount of the asset or the recoverable amount of the cash generating unit to which the asset belongs is less than its carrying amount, the carrying amount is reduced to its recoverable amount. The reduction is treated as an impairment loss and is recognized in the Profit and Loss account. If at the Balance Sheet date there is an indication that if a previously assessed impairment loss no longer exists, the recoverable amount is reassessed and the asset is reflected at the recoverable amount.

xiii. CAPITAL RESERVE ACCOUNT

Any expense incurred for raising of funds from securities are adjusted against capital reserve account.

xiv. CHANGES IN ACCOUNTING POLICIES

There are no changes in the accounting policies during the reported period.

xv. FOREIGN CURRENCY TRANSACTIONS:

1) Transactions in foreign currencies are recognised at the prevailing exchange rates on the transaction dates. Realised gains and losses on settlement of foreign currency transactions are recognised in the Statement of Profit and Loss.



Particulars	As at 31st March, 2017		As at 31st March, 2016	
	No. of Shares	Amount	No. of Shares	Amount
(A) Share Capital				
Authorised Capital				
Equity Shares of Rs.10/- each.	3,50,00,000	3,500	3,50,00,000	3,500
	3,50,00,000	3,500	3,50,00,000	3,500
Issues, Subscribed and Paid up:				
Equity Shares of Rs. 10/- each.*	50,000	5.00	50,000	5.00
Total	50,000	5.00	50,000	5.00
(B) Share capital suspense account				
Share capital suspense account				
(Refer Note 1B(d))	2,05,78,000	2.058	-	-
Total	2,05,78,000	2.058	-	-

(C) Reconciliation of the Shares outstanding at the beginning and at the end of the year:			
Issued, Subscribed and Paid up capital			
At the beginning of the Year	50,000	5.00	50,000
Share issued during the Year	-	-	-
Issued, Subscribed and Paid Up capital at the end of year	50,000	5.00	50,000

(D) Terms / Rights attached to Equity Shares
The Company has only one class of equity shares having a par value of 10/- per share. Each holder of equity shares is entitled to one vote per share. The company declares and pays dividends in Indian Amounts in ₹. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing annual general meeting.
During the year ended 31st March 2017, no dividend is declared by Board of Directors. (Previous year - Nil)
In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

(E) Shares held by the holding company: Refer Note 1(B)

Name of Shareholder	As at 31st March, 2017		As at 31st March, 2016	
	No. of Shares	% Shareholding	No. of Shares	% Shareholding
Omkar Speciality Chemicals Limited	-	-	50000	100%
Omkar Pravin Herlekar	5251500	25.46%	-	-
Pravin Herlekar	2290821	11.11%	-	-
Total	75,42,321	36.56%	50,000	100%

Reflects proportionate number of shares that shall be issued pursuant to the Scheme (G) Aggregate number of bonus shares issued and shares issued for consideration other than cash during the period of five years immediately preceding the reporting date
The company has not issued any bonus shares nor has there been any buy back of shares during five years immediately preceding 31.03.2017

Note No.	Particulars	As at March 31, 2017	As at March 31, 2016
RESERVE AND SURPLUSES			
Capital Reserve			
Opening Balance			
Add: Arising pursuant to the scheme (refer Note 1B(c))	5,553.70	-	-
Closing Balance	5,553.70	-	-
Profit & Loss Account			
Opening Balance			
Add: Profit for the year	(62.53)	-	-
Total	5,491.17	-	-

Particulars	As at March 31, 2017			As at March 31, 2016		
	Long term	Current maturities of Long-Term*	Short Term	Long term	Current maturities of Long-Term*	Short Term
BORROWINGS						
Secured Borrowings						
1) From Banks	3,154.61	1,191.68	2,318.51	-	-	-
2) From Financial Institutions & Others	8.92	-	-	-	-	-
TOTAL SECURED BORROWINGS	3,163.54	1,191.68	2,318.51	-	-	-
Unsecured Borrowings						
1) Borrowings from others	5,302.22	-	-	35.04	-	-
TOTAL UNSECURED BORROWINGS	5,302.22	-	-	35.04	-	-
Total	8,465.76	1,191.68	2,318.51	35.04	-	-

Note No.	Particulars	As at March 31, 2017	As at March 31, 2016
6 DEFERRED TAX			
Deferred Tax Assets/(Liability)			
On account of difference between net book value of the capital assets as per books vis-à-vis written down value as per Income Tax Act	(3,186.58)	-	-
Deferred Tax Assets:			
On account of gratuity	125.81	-	-
Bonus & Leave encashment	19.15	-	-
Accumulated Loss Urdhwa as on 31-03-2015	3,004.41	-	-
Net Difference Asset	(37.20)	-	-
Tax rate in %	34.61	-	-
Net Deferred Tax Assets (Liabilities)	(12.87)	-	-
Deferred Tax Liability recognised till previous year	(254.67)	-	-
Deferred Tax Liability for Current Year	(241.80)	-	-

Note No.	Particulars	As at March 31, 2017	As at March 31, 2016
10. SHORT TERM PROVISIONS			
Others Provisions			
Income Tax Payable (Net)	206.92	-	-
Provision for Expenses	162.27	-	-
Total	369.19	-	-

Particulars	As at 31st March, 2017		As at 31st March, 2016	
	As at 01.04.2016	As at 31.03.2017	As at 01.04.2016	As at 31.03.2017
A TANGIBLE ASSETS				
Computer and Peripherals	609.08	14.54	623.63	27.94
Air Conditioner	1.65	2.49	2.157	3.60
Effluent Treatment	2.40	2.13	1.65	0.13
Electricity & Electrical Equipment	207.82	0.87	2.40	0.01
Factory Building	2,788.51	478.46	3,283.07	50.52
Future & Spare	2,279.29	868.35	8,082.32	1,371.83
Furniture	9.86	45.38	9.35	0.00
Motor Car	37.84	45.38	37.84	45.38
Plant & Machinery F&D and Lab & O.C.	1,483.15	208.15	1,691.24	69.24
Office Equipment	8.48	4.99	13.00	148.01
Laboratory Equipments	23.79	1.87	13.48	5.86
SUB TOTAL (A)	12,485.64	1,636.03	14,107.28	2,067.23
B INTANGIBLE ASSETS				
Patent and Process	588.46	588.46	588.46	588.46
SUB TOTAL (B)	588.46	588.46	588.46	588.46
C CAPITAL WORK IN PROGRESS				
Intangible	17.14	17.14	17.14	17.14
Tangible	4,384.78	2,679.16	4,130.34	2,933.99
SUB TOTAL (C)	4,401.92	2,696.30	4,147.48	2,951.13
TOTAL ASSETS	17,486.01	4,902.79	18,842.22	5,626.82

Particulars	March 31, 2017		March 31, 2016	
	March 31, 2017	March 31, 2016	March 31, 2017	March 31, 2016
20 REVENUE FROM OPERATION				
Sale of Products				
Sales Domestic (Gross)	21,270.22	-	21,270.22	-
Sales Export (Gross)	642.13	-	642.13	-
Other Operating Revenue	1.68	-	1.68	-
Revenue From Operation (Gross)	21,914.04	-	21,914.04	-
Less: Excise Duties	1,947.79	-	1,947.79	-
Revenue From Operation (Net)	19,966.25	-	19,966.25	-
21 OTHER INCOME				
Interest on Fixed Deposit with Bank	7.29	-	7.29	-
Interest on Sales tax & IT refund received	19.89	-	19.89	-
Total	27.18	-	27.18	-
22 COST OF MATERIAL CONSUMED				
Opening Stock of Raw Materials	558.73	-	558.73	-
Add: Purchases	14,452.34	-	14,452.34	-
Less: Closing Stock of Raw Materials	844.03	-	844.03	-
Total	14,167.04	-	14,167.04	-
23 Changes in inventories of Finished Goods, Work in progress and Stock in Trade				
Finished Goods	1,019.93	-	1,019.93	-
Work in progress	405.53	-	405.53	-
Opening Stock	1,423.46	-	1,423.46	-
Closing Stock	630.12	-	630.12	-
Finished Goods	1,871.70	-	1,871.70	-
Work in progress	2,501.82	-	2,501.82	-
Changes in inventories of Finished Goods, Work in progress and Stock in Trade	(1,078.36)	-	(1,078.36)	-
24 EMPLOYEE BENEFITS EXPENSES				
Salaries, Wages & Other Benefits	948.63	-	948.63	-
Office Personnel Expenses	302.28	-	302.28	-
Total	1,250.91	-	1,250.91	-
Note: Salaries, Wages & Other Benefits, recognized as expense for the year is as under:				
Salaries and Wages	408.50	-	408.50	-
Director Remuneration	32.79	-	32.79	-
Bonus Gratuity and other incentives	80.56	-	80.56	-
Contribution to Labour Welfare Fund	0.10	-	0.10	-
Contract Labour Charges	948.63	-	948.63	-

12 NON CURRENT INVESTMENTS		Rs in Lakhs	
	As at March 2017	As at March 2016	
Investment in quoted equity instruments (fully paid-up)			
1000 (P.Y. Nil) Shares Investment in Saraswat Bank Co-op Ltd of INR 10/- each	0.10	-	-
Total	0.10	-	-
13 LONG TERM LOANS AND ADVANCES			
(Unsecured, Considered Good)			
Deposits	49.81	-	-
Total	49.81	-	-
14 OTHER NON CURRENT ASSETS			
Preliminary Exp Not W/off	28.09	35.09	-
Total	28.09	35.09	-
15 INVENTORIES			
Packing Material and Engineering Items Inventory	-	-	-
Raw materials	844.03	-	-
Work-in-progress	1,871.70	-	-
Finished products	630.12	-	-
Total	3,345.85	-	-
The value of the closing stock of raw materials, Packing Material, stores, work in process and finished goods has been arrived at on the basis of the records maintained and certified by the Management.			
16 TRADE RECEIVABLES			
(Unsecured and Considered Good)			
More than six months	-	-	-
Others	3,554.17	-	-
Less: Provision for doubtful Trade Receivables	(50.00)	-	-
Total	3,504.17	-	-
17 CASH AND BANK BALANCES			
Cash and Cash Equivalents	12.83	5.00	-
Balance with Banks	-	-	-
Fixed Deposit With Axis Bank as a Margin	-	-	-
Money & BOB	102.02	-	-
Cash on hand	1.38	-	-
Total	116.23	5.00	-
17.1 Disclosure on specified bank notes (SBNS)			
During the year, the Company had SBNS/other denomination notes (other notes) as defined in the MCA notification G.S.R. 308 (E) dated 31 March 2017. The denomination wise details of the SBNS and other notes held and transacted during the period from 8 November 2016 to 30 December 2016 is given below:			
Particulars	SBNS	Other notes	Total
Closing cash on hand as at 30th November 2016			
hand as at 30th November 2016	12.26	3.40	15.66
(+) Permitted Receipts	7.27	7.27	14.54
(-) Amount deposited in banks	6.79	6.79	13.58
Closing cash on hand as at 30th December 2016			
hand as at 30th December 2016	12.26	3.88	16.14
# For the purpose of this clause, the term 'Specified Bank Notes' shall have the same meaning provided in the Government of India notification S.O. 3407 (E), dated 8 November 2016.			
18 SHORT TERM LOANS AND ADVANCES			
(Unsecured, Considered Good)			
Advances to suppliers	100.00	-	-
& Other Vendors	33.49	-	-
Advances to Capital Supplier	5.55	-	-
Prepaid Expenses	-	-	-
Advances with Government Authorities	744.40	-	-
Total	883.43	-	-
19 OTHER CURRENT ASSETS			
Other Current Assets	0.28	-	-
Advances to vendors	129.77	-	-
Total	130.05	-	-

Particulars	March 31, 2017		March 31, 2016	
	March 31, 2017	March 31, 2016	March 31, 2017	March 31, 2016
24.1 Actuarial Gain/(Loss) Recognized				
Actuarial Gain/(Loss) for the period (Obligation)	16.19	-	16.19	-
Actuarial Gain/(Loss) for the period (Plan Assets)	-	-	-	-
Total Gain/(Loss) for the period	16.19	-	16.19	-
Actuarial Gain/(Loss) recognized for the period	16.19	-	16.19	-
Unrecognized Actuarial Gain/(Loss) at the end of the period	-	-	-	-
24.2 Changes in the present value of obligation:				
Present value of obligation at beginning of period	98.01	-	98.01	-
Add: Interest Cost	7.31	-	7.31	-
Add: Current Service Cost	39.42	-	39.42	-
Add: Past Service Cost	-	-	-	-
Less: Benefits paid	(2.75)	-	(2.75)	-
Add: Actuarial (gain)/loss on obligation	(16.19)	-	(16.19)	-
Present value of obligation at end of period	125.81	-	125.81	-
24.3 Amounts recognized in the balance sheet				
Present value of obligation at the end of the period	125.81	-	125.81	-
Less: Fair Value of Plan Assets at end of period	-	-	-	-
Funded Status	(125.81)	-	(125.81)	-
Unrecognized Past Service Cost	-	-	-	-
Net Asset/(Liability) recognized in the Balance Sheet	(125.81)	-	(125.81)	-
24.4 Expenses recognized in the Profit and Loss account				
Current Service Cost	39.42	-	39.42	-
Add: Interest Cost	7.31	-	7.31	-
Add: Past Service Cost	-	-	-	-
Add: Net Actuarial (Gain)/Loss recognized in the Profit and Loss account	(16.19)	-	(16.19)	-
Expenses recognized in the Profit and Loss account	30.55	-	30.55	-
24.5 Assumptions used in actuarial valuation of gratuity				
Interest/Discount Rate	0.07	-	0.07	-
Rate of increase in compensation	0.15	-	0.15	-
Rate of return (expected) on plan assets	-	-	-	-
Employee Attrition Rate (Past Service)	0 to 42: 0%	-	0 to 42: 0%	-
25 FINANCE COST				
Interest Expenses (Note II)	860.54	-	860.54	-
Other Borrowing Cost	71.52	-	71.52	-
Total	932.06	-	932.06	-

The following tables set

Note No	Particulars	March 31 2017	March 31 2016	
	Interest Expenses			
	Includes :			
	On loans for fixed periods from banks	10.98	-	
	On cash credit and other facilities from banks	849.56	-	
	Total	860.54	-	
26	OTHER EXPENSES			
	Other Manufacturing Expenses			
	Power & Fuel Expenses	525.88	-	
	Water Charges	77.05	-	
	Freight Inward	61.16	-	
	Processing Charges	50.58	-	
	Laboratory Expenses	16.98	-	
	Consumable Stores	18.75	-	
	Other Manufacturing Expenses	189.01	-	
	Sundry Factory Expense	16.46	-	
	Sub Total (A)	955.85	-	
	Administrative, Selling and Distribution Expenses			
	Conveyance & Traveling Expenses	23.16	-	
	Sales Promotion Expenses	19.27	-	
	Freight & Transportation	28.93	-	
	Commission on Sales	17.63	-	
	Telephone/postage/Internet Charges	29.09	-	
	Insurance	22.03	-	
	Professional Charges	85.67	-	
	Repairs & Maintenance	12.79	-	
	Rates & Taxes	2.42	-	
	Rent	0.92	-	
	Misc. Exp	51.22	-	
	Discounts	2.49	-	
	Forex Gain/ Loss on	19.10	-	
	Other expenses	16.54	-	
	Auditor Remuneration (Refer Note No. 29)	1.65	-	
	Provision for Doubtful Debts	15.00	-	
	Demerger Expenses	5.65	-	
	Loss on sale of Motor Car	1.65	-	
	Sub Total (B)	414.75	-	
	Total (A+B)	1,370.60	-	
27	Exceptional Items			
	Impairment of Work in Progress Written off (Refer Note No. 23.1)	2,619.10	-	
	Impact of Profit and Loss for the year of 2015-16 (Refer Note No. 23.2)	442.19	-	
		3,061.30	-	
27.1	Exceptional items consist of the difference between the fair value and book value of assets taken over from Demerged company amounting to Rs. 26,19,10,397. The Same has been charged to the Profit & Loss Account of the company in the terms of the composite scheme of arrangements as sanctioned by the honorable NCLT Mumbai Bench vide order dated 13.04.2017			
27.2	Impact represents of Profit and Loss for the year of 2015-16 is taken after restating of financial statements in the terms of the composite scheme of arrangements as sanctioned by the honorable NCLT Mumbai Bench vide order dated 13.04.2017.			
28	Related Party Transaction			
	(Rupees in Lakhs, except for share detail otherwise stated)			
	Party	Relationship		
	Mr. Shivnand Hegde	Director		
	Mr. Sumant Kharsambale	Director		
	M/s Omkar Speciality Chemicals Limited	Holding Company		
	M/s Harishree Aromatics & Chemicals Pvt Ltd	Associate Company-Common control/Exist		
Sr No.	Nature of Transaction	Relationship	As on March 2017	As on March 2016
1	Transaction with related parties			
	Directors Remuneration	Director/Key Management Personnel	32.79	-
	Purchase of Goods Omkar Speciality Chemicals Limited	Holding Company	33.80	-
	Sale of Goods Omkar Speciality Chemicals Limited	Holding Company	280.71	-
	Purchase of Assets Omkar Speciality Chemicals Limited	Holding Company	269.37	-
	Loan Taken Omkar Speciality Chemicals Limited	Holding Company	687.35	35.00
	Processing Charges Common Co. Pvt. Ltd.	Director	5.20	-
2.	Outstanding balances of related parties			
	Omkar Speciality Chemicals Limited	Holding Company	2959.41	35.00
	Harishree Chemicals Common Co. Pvt. Ltd.	Director	1.08	-
29	Payments to Auditors			
	(a) As Auditor		1.25	-
	(b) For Taxation matter		1.65	-
	Total		1.65	-
30	Value of Imported raw materials & Stores consumed and percentage of consumption: Raw Material			
	Imported		387.43	-
	Percentage		2.73%	-
	Indigenous		13,779.61	-
	Percentage		87.17%	-
	TOTAL		14,167.04	-
	Percentage		100%	-
31	Consumable Stores			
	Imported		-	-
	Percentage		-	-
	Indigenous		544.63	-
	Percentage		100%	100%
	TOTAL		544.63	-
	Percentage		100%	100%
32	Earnings and Expenditure in Foreign Currency :			
	Earnings in Foreign Exchange			
	Value of Export (FOB)		642.13	-
	Expenditure in Foreign Currency			
	Purchase of Raw Material		387.43	-
	Capital Expenditure			
	Other Expenses		21.31	-
	Interest		-	-
	Dividend remitted in foreign currency		-	-
	Value of Import on CIF Basis			
	Raw Material		387.43	-
	Capital Goods		-	-



Note No	Particulars	March 31 2017	March 31 2016	
33	Basic and Diluted Earnings Per Share is calculated as under:			
	Profit attributable to Equity Shareholders	(62.53)	-	
	Less: Profit attributable to Preference Shareholders	-	-	
	Profit attributable to Equity Shareholders	(62.53)	-	
	Weighted average number of Equity Shares:			
	-Basic	50,000.00	-	
	-Diluted	50,000.00	-	
	Earnings per Share (in Rs.)			
	Basic	(125.07)	-	
	Diluted	(125.07)	-	
	Basic Earnings Per Share are computed by dividing net profit after tax by weighted average no of equity shares.			
34.	Previous year figures have been re-grouped and reclassified wherever necessary to conform to this year's classification. In view of Acquisition of API business, the reported previous year figures are not directly comparable.			
K.	DETAILS OF OTHER GROUP COMPANIES:			
	CAPITAL STRUCTURE OF AMARNATH SECURITIES LIMITED:			
1)	CAPITAL STRUCTURE OF AMARNATH SECURITIES LIMITED:			
	Share Capital			
	Number of Shares			
	Rs.			
	Authorised Share Capital:			
	Equity Shares of Rs. 10 each	40,00,000	4,00,00,000	
	TOTAL	40,00,000	40,00,00,000	
	Issued, Subscribed and fully paid up:			
	Equity Shares of Rs. 10 each	3,000,200	3,00,02,000	
	TOTAL	3,000,200	3,00,02,000	
2)	CAPITAL STRUCTURE OF HARISHREE AROMATICS AND CHEMICALS PVT. LTD.:			
	Equity Shares of Rs. 10 each	3,30,000	33,00,000	
	TOTAL	3,30,000	33,00,000	
	Issued, Subscribed and fully paid up:			
	Equity Shares of Rs. 10 each	3,30,000	33,00,000	
	TOTAL	3,30,000	33,00,000	
3)	CAPITAL STRUCTURE OF SVAKS BIOTECH INDIA PVT LTD:			
	Authorised Share Capital:			
	Equity Shares of Rs. 10 each	50,000	5,00,000	
	TOTAL	50,000	5,00,000	
	Issued, Subscribed and fully paid up:			
	Equity Shares of Rs. 10 each	25,000	2,50,000	
	TOTAL	25,000	2,50,000	
4)	CAPITAL STRUCTURE OF OMKAR SPECIALITY CHEMICALS LIMITED:			
	Authorised Share Capital:			
	Equity Shares of Rs. 10 each	4,19,50,000	4,195	
	Preference Share of Rs 10 each	27,50,000	275	
	TOTAL	4,47,00,000	4,470	
	Issued, Subscribed and fully paid up:			
	Equity Shares of Rs. 10 each	2,05,78,004	2,057,800	
	TOTAL	2,05,78,004	2,057,800	
	Financial Information of Group Companies (Year Ended March 31, 2017)			
	Amarnath Securities Limited (Rs)			
	Total Income	3425195		
	Total Expenditure	1632127		
	Profit/(Loss) before Tax	1793068		
	Provision for Tax (including Deferred Tax and Prior period adjustment)	(581064)		
	Profit/(Loss) after tax	1212004		
	Harishree Aromatics and Chemicals Private Limited (Rs in Lakhs)			
	Total Income	1846.32		
	Total Expenditure	1842.33		
	Profit/(Loss) before Tax	3.99		
	Provision for Tax (including Deferred Tax and Prior period adjustment)	(13.37)		
	Profit/(Loss) after tax	(9.38)		
	Omkar Speciality Chemicals Ltd (Rs in Lakhs)			
	Total Income	34726.48		
	Total Expenditure	31527.89		
	Profit/(Loss) before Tax	(3122.79)		
	Provision for Tax (including Deferred Tax and Prior period adjustment)	(565.98)		
	Profit/(Loss) after tax	(2556.82)		
	Svaks Biotech India Private Limited (Rs)			
	Total Income	603680		
	Total Expenditure	23133		
	Profit/(Loss) before Tax	580547		
	Provision for Tax (including Deferred Tax and Prior period adjustment)	0		
	Profit/(Loss) after tax	580547		
L.	THERE ARE NO OUTSTANDING LITIGATIONS AND DEFAULTS OF OMKAR SPECIALITY CHEMICALS LIMITED (TRANSFEREE ENTITY), PROMOTERS, DIRECTORS OR ANY OF THE GROUP COMPANIES:			
M.	PARTICULARS OF HIGH, LOW AND AVERAGE PRICES OF THE SHARES OF THE LISTED TRANSFEROR ENTITY I.e. OMKAR SPECIALITY CHEMICALS LIMITED:			
	Particulars	2015	2016	2017
	High:			
	NSE	164.80	183.20	155.90
	BSE	162.40	183.00	155.30
	Low:			
	NSE	151.35	172.75	151.95
	BSE	151.60	173.70	151.80
	Average prices:			
	NSE	157.71	178.34	153.31
	BSE	155.54	178.25	153.64
N.	ANY MATERIAL DEVELOPMENT AFTER THE DATE OF THE BALANCE SHEET:			
	The Hon'ble National Company Law Tribunal of Mumbai Bench has approved the Composite Scheme of Arrangement between Omkar Speciality Chemicals Limited and Lasa Supergenesis Limited vide its order dated April 13, 2017.			

इंजीनियरिंग का उत्कृष्ट नमूना सरदार सरोवर बांध

भाय दामोई (वडोदरा, गुजरात), 17 सितंबर



प्रधानमंत्री नरेंद्र मोदी ने नर्मदा नदी पर जने वाली महत्वाकांक्षी परियोजना सरदार सरोवर नर्मदा बांध का आज लोकार्पण करते हुए पिछले सात दशकों में इस परियोजना में आई नमाम बाधाओं का उल्लेख किया और उम्मीद जताई कि यह परियोजना नए भारत के निर्माण में सवा सौ करोड़ भारतीयों के लिए प्रेरणा का काम करेगी।

सरोवर बांध के कुछ तथ्य

- नर्मदा जिले के केवडिया में तत्कालीन प्रधानमंत्री पं. जवाहरलाल नेहरू द्वारा सरदार सरोवर बांध की आधारशिला रखने के 56 साल बाद सरोवर को प्रधानमंत्री नरेंद्र मोदी ने अपने जन्मदिन पर बांध का उद्घाटन किया।
- बांध में 30 गेट हैं। प्रत्येक गेट का वजन 450 टन है और इन्हें बंद करने में एक घंटा का समय लगेगा। अमेरिका में गेट कोली डैम के बाद यह दुनिया का दूसरा सबसे बड़ा कंक्रीट गेट डैम है।
- यह बांध राज्य में 8,00,000 हेक्टेयर भूमि की सिंचाई में मदद करेगा और 131 शहरी केंद्रों तथा 9,633 गांवों (गुजरात के कुल 18,144 का 53 प्रतिशत) को पीने का पानी उपलब्ध कराएगा। इसके अतिरिक्त महाराष्ट्र और राजस्थान के सिंचित भागों में सिंचाई की सुविधा उपलब्ध कराएगा।

है, जिस प्रकार पास लोहे को स्पर्श कर सोना बना देता है उसी प्रकार इस बांध का पानी जिस सूखी जमीन पर जाया वह जमीन सोना उगलने लगी। उन्होंने कहा कि भारत को दूर भुजाएँ हैं। परिश्रमी और पूर्वी भारत। जिस प्रकार नर्मदा बांध से पश्चिमी भारत की सिंचाई एवं पेय जल समस्या को दूर करने में एक बड़ी मदद मिलेगी उसी प्रकार यह चाहे है कि पूर्वी भारत की बिजली की समस्या को दूर करने के लिए बड़े स्तर पर प्रयास हो।


प्रधानमंत्री ने नर्मदा बांध के पास बने वाली सरदार पटेल को 182 मीटर ऊंची प्रतिमा स्टेच्यू ऑफ यूनिटी का उद्घाटन करते हुए कहा कि इससे क्षेत्र के उपजद को काफी मदद मिलेगी। उल्लेखनीय है कि मोदी ने गुजरात के निर्माण को खते के दौरान नर्मदा बांध के लिए अन्तर्गत भी किया था। इससे पहले प्रधानमंत्री ने सरदार सरोवर नर्मदा बांध परियोजना का लोकार्पण किया। इस बांध को ऊंचाई को 138-68 मीटर तक बढ़ाया गया है। मोदी का आज जन्म दिन है। मोदी ने इस अवसर पर सरदार सरोवर बांध पर नर्मदा नदी को वैदिक मंत्रोच्चार के बीच पूजा अर्चना की। उन्होंने इससे बाद सरदार पटेल को 182 मीटर की विशालकाय प्रतिमा के निर्माण का आज का भी लिया। स्टेच्यू ऑफ यूनिटी नामक यह प्रतिमा उन्हाई को दृष्टि से दुनिया के सबसे ऊंची प्रतिमा होगी। यह अभी तक की सबसे ऊंची प्रतिमा स्टेच्यू ऑफ यूनिटी से भी ऊंची है। इस अवसर पर प्रधानमंत्री के साथ केंद्रीय मंत्री नितिन गडकरी, गुजरात के राज्यपाल ओपी कोहली, मुख्यमंत्री विजय रूपानी, पूर्व मुख्यमंत्री आनंदीबेन पटेल सहित विभिन्न प्रमुख नेता मौजूद थे।

के करोड़ों किसानों का भाग्य बदलेगा। नर्मदा बांध परियोजना में हुए विलंब का उल्लेख करते हुए प्रधानमंत्री ने कहा कि वह इसे राजनीति से नहीं जोड़ेंगे। नर्मदा बांध परियोजना में हुए विलंब का उल्लेख करते हुए प्रधानमंत्री ने कहा कि वह इसे राजनीति से नहीं जोड़ेंगे। नर्मदा बांध परियोजना में हुए विलंब का उल्लेख करते हुए प्रधानमंत्री ने कहा कि वह इसे राजनीति से नहीं जोड़ेंगे।

इधर, प्रख्यात सामाजिक कार्यकर्ता और पर्यावरणविद मेधा पाटकर ने कहा है कि नर्मदा नदी पर गुजरात में बांधों का निर्माण के बीच लोचप्रभा राजनीतिवादी लोग के निर्माण किया गया है। ऐसे में बांधों के निर्माण के कार्य में काफी गति आई और बांध का समय इस परियोजना का काम तेजी से नहीं बढ़ा। उन्होंने कहा कि नर्मदा बांध पानी पास

सितंबर से होगी निर्यात वृद्धि की परीक्षा

न्यू देहली, 17 सितंबर



आरत में निर्यात में सालाना आधार पर 10.3 फीसदी की उछाल और लगातार 12 फीसदी तक बढ़ती रहे बावजूद निर्यात और अर्थव्यवस्था का माहना है कि वस्तु निर्यात की असली परीक्षा आने वाले महीनों में होगी।

जोएस्टी से जुड़े मुद्दों को सुलझाने के लिए सरकार ने राजस्थान सहस्रमुख अर्थव्यवस्था की अनुसंधान में एक समिति का गठन किया है।

इसकी वजह यह है कि वस्तु एवं सेवा कर (जीएसटी) लागू होने के बाद दो महीने से देय रिफंड का मुद्दा बकरार है, निर्यात नकदी की किल्लत को शाकाकार कर रहे हैं और रुपये के आने वाले महीनों में और मजबूत होने की संभावना है। भारतीय निर्यातकों के संगठन के महानिदेशक अजय सहाय ने कहा, 'हमें यह याद रखने की जरूरत है कि आगस्त, 2016 तक निर्यात में लगातार गिरावट आ रही थी और इसलिए सालाना आधार पर तुलना कम आधार पर होगी। सितंबर, 2016 के बाद निर्यात में बढ़ोतरी शुरू हुई थी और सितंबर, 2017 के आंकड़े उल्लेखनीय समायोजित होंगे।' निर्यात क्षेत्र लगातार इस मांग को उठा रहा है कि जोएस्टी के तहत चुकाए गए करों के रिफंड को प्रक्रिया बहुत जटिल है। निर्यातकों को वस्तु आयात पर एकजुट जोएस्टी का भूतनात करना होगा और फिर जोएस्टी के तहत इसके रिफंड का दावा करना होगा। उनका कहना है कि इससे निर्यातक कंपनियों को अपना कामकाज शुरू कर चलाना पड़ रहा है। फियो का कहना है कि इसके परिणामस्वरूप विभिन्न उद्योगों और उपाय श्रेणियों के निर्यात आँदरे में 15 फीसदी तक को कमी आई है। सहाय ने कहा कि मुख्यतः उन निर्यात आँदरे में कमी आई है जिसकी आवृत्ति अत्यंत कम होनी थी। उन्होंने कहा कि क्रेडिट को माह के कारण निर्यात के आँदरे में तेजी आई है। सितंबर के निर्यात आँदरे में यह परिवर्तन होगा।

दूसरी तरफ इंजीनियरिंग सामान के निर्यात में तेजी आई है। इंजीनियरिंग एक्सपोर्ट्स प्रमोशन कारोर्स ऑफ इंडिया के चेयरमैन टी एस परीने ने कहा, 'इंजीनियरिंग सामान का निर्यात सम्मानजनक प्रति से बढ़ रहा है और इसका कारण यह है कि आयात धारुओं में तेजी आई है। लेकिन रुपये की कोमल चिंता का विषय नहीं।' अर्थव्यवस्था में रुपये के लगातार मजबूत होने का अनुमान जताया है। रुपये के लगातार मजबूत होने से निर्यात

बढ़ोतरी के प्रभावित होने और भारतीय कंपनियों की प्रतिस्पर्धी क्षमता घटने की संभावना है। इंडिया टैरिफ्स के मुख्य अर्थशास्त्री देवेन्द्र पंत ने कहा, 'हमारे आकलन के मुताबिक इस वित्त वर्ष में रुपया कम से कम 2 से 2.5 फीसदी तक मजबूत होगा। विदेशी पोर्टफोलियो निवेशकों ने भारत में 25 अरब डॉलर से अधिक का निवेश किया है और इसके अभी और बढ़ने की संभावना है क्योंकि चीन भी निवेश अवसरों को खोज रहा है।' उन्होंने कहा कि कर, उधार कोशिका और दूसरे कई भूराजनीतिक कारकों से निर्यात की तेजी को प्रभावित नहीं हुआ है। बांधों शुकनार को रुपया डॉलर के मुकाबले 64.08 के स्तर पर बंद हुआ था। इस साल अब तक रुपया डॉलर के मुकाबले 6 फीसदी मजबूत हो चुका है जबकि विदेशी संस्थागत निवेशकों ने भारत में 6.76 अरब डॉलर डॉक्यूमेंट में और 20.31 अरब डॉलर डेम् में झोके हैं। जोएस्टी से जुड़े मुद्दों को सुलझाने के लिए सरकार ने राजस्थान सहस्रमुख अर्थव्यवस्था की अनुसंधान में एक समिति का गठन किया है। यह समिति निर्यातकों की समस्या को सुलझाने के लिए एक संस्थागत व्यवस्था बनाने की कोशिश करेगी। इस दौरान सरकार ने इस क्षेत्र को कुछ समस्याओं को सुलझाने की कोशिश की है। मकेंडाइज योजनाओं से प्रभावित इंडिया जैसी निर्यात संबद्ध व्यंजनों में शेयरों की किल्ली पर जोएस्टी के तहत 12 फीसदी कर लगाया था लेकिन एक ही महीने में इसे घटाकर 5 फीसदी कर दिया गया। साथ ही 20 लाख रुपये से कम डॉलर वार्षिक वाले कारोबार को जोएस्टी के तहत पंजीकरण करने को जरूरत नहीं है। कच्चे तेल की कोमल बढ़ने से पेट्रोलियम उत्पादों के निर्यात में आठ तेजी भी एक निर्यातकों के लिए अत्यंत लाभ हो सकता है। अमेरिका में चक्रवर्ती तुलना हार्वी के गुजरने के बाद तेल शोकक कारखानों में एक फायदा स्थिति बहाल होने से कच्चे तेल की कोमल में फिर गिरावट आ सकती है।